LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRXBiotechnology
-$0.39 today
- Market cap
- $1.30B
- Beta
- 0.71
- P/E (TTM)
- -21.4
- EPS (TTM)
- -$1.39
Volume 0.36M
Average 0.23M
LBRX Account Payables
Amounts the company owes suppliers for goods and services received.
LB Pharmaceuticals Inc Common StockNASDAQ: LBRX
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables rises 1021.1% from a year ago
Account payables stood at $7.12M at the end of Q1 FY2026, up 1021.1% from a year earlier and up 234.7% from the prior quarter. Over 3 fiscal years it compounded at +138.9% a year.
Context
- Account payables amounted to 1.8% of total assets at the end of Q1 FY2026, down 1.5 pp from a year earlier.
- Account payables increased in 2 of the last 3 fiscal years.
What to watch
Whether account payables keeps rising in the next quarterly balance sheet after a +1021.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 2.13M USD
- Year-over-year change
- -8.3%
- 3-year CAGR
- +138.9%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.13M | -8.3% |
| FY2024 | 2024-12-31 | 2.32M | +67.0% |
| FY2023 | 2023-12-31 | 1.39M | +790.4% |
| FY2022 | 2022-12-31 | 156K | — |
Account Payables vs competitors
How LBRX compares with its peers on the latest reported figures
- LBRX's Mar 2026 account payables of $7.12M is the 4th highest of the 10 companies compared; the peer median is $5.21M.
- Its year-over-year change of +1021.1% is the highest of 10, against a peer median of +14.3%.
- Account payables amounts to 1.8% of total assets for LBRX, versus a peer median of 1.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $16.33M | -24.9% | -5.1% | 0.9% | |
| Jun 2026 | $11.81M | +8.9% | +6.1% | 1.0% | |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | $9.28M | +14.3% | +36.3% | 0.9% |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $7.12M | +1021.1% | +138.9% | 1.8% |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $6.56M | +206.7% | +42.4% | 1.3% |
| Mar 2026 | $5.21M | +9.2% | +26.4% | 1.9% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $5.06M | +380.7% | -22.1% | 3.3% |
| Mar 2026 | $3.37M | +143.4% | +5.4% | 1.2% | |
| Jun 2026 | $1.45M | +61.5% | -13.0% | 0.0% | |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding LBRX) | $5.21M | +14.3% | +5.7% | 1.0% | |
Competitors are the stored peer set for LBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
Intrinsic Alpha fair value
Locked
Current Price
$40.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.